Analyst Viewpoint
Rise in prevalence of chronic diseases is fueling the therapeutic plasma exchange market size. Therapeutic Plasma Exchange (TPE) is gaining traction for the treatment of autoimmune diseases and neurological disorders as it helps remove large amounts of disease-causing agents that attack the body and cause symptoms.
Emergence of COVID-19 is likely to offer lucrative opportunities to players in the global therapeutic plasma exchange industry. Vendors are providing customizable solutions that can be adapted to different patient needs and treatment protocols. They are also developing advanced polymeric materials for use in membrane separation systems in plasmapheresis machines.
Therapeutic Plasma Exchange (TPE) is a procedure used for the treatment of various neurological disorders, renal disorders, hematology disorders, and metabolic disorders. In the procedure, an apheresis machine is used to remove and discard the filtered plasma and reinfused with red blood cells and fluids such as plasma or albumin. This process is also called plasmapheresis and is employed in the treatment of various chronic diseases such as Multiple Sclerosis (MS), myasthenia gravis, Guillain-Barré syndrome, cryoglobulinemia, and thrombotic thrombocytopenic purpura.
TPE focuses on removing various agents in the plasma, such as an antibody, toxin, or abnormal protein, that are causing the clinical symptoms of a disease. Patient experiences and outcomes with therapeutic plasma exchange therapy can vary widely depending on the underlying condition being treated. Technological advancements have led to the availability of upgraded apheresis machines that help remove pathological components in the blood. New single-door platelet and plasma machines extract 500 ml plasma directly from the donor whereas in a normal process of plasma extraction, 350 to 400 ml blood is collected.
TPE is used for the treatment of various chronic diseases. It is employed to eliminate higher molecular weight substances, such as immunoglobulins or immune complexes, from plasma. TPE is recommended for the treatment of post-renal transplant rejection, anti-glomerular basement membrane (GBM) disease, Wegener's granulomatosis, and other renal diseases.
High incidence of chronic diseases is propelling the therapeutic plasma exchange market development. According to the paper ‘Incidence, Risk Factors, Treatment, and Consequences of Antibody-mediated Kidney Transplant Rejection: A Systematic Review, published in the journal PubMed in 2021, the incidence of Acute Antibody-mediated Kidney Transplant Rejection was 1.1%-21.5%. Antibody-mediated rejection is common and associated with an increased risk of death-censored graft failure.
Increasing prevalence of autoimmune diseases and neurological disorders is projected to spur the therapeutic plasma exchange market growth in the near future. TPE is widely utilized in the treatment of autoimmune diseases. It helps remove large amounts of disease-causing agents that attack the body and cause symptoms. TPE is typically employed alone or in conjunction with other treatment options such as intravenous immunoglobulins (IVIG) and corticosteroids.
TPE is effective in the treatment of MS. It removes proteins that attack tissues in the body. These proteins are found in blood plasma. According to the paper, ‘Rising Prevalence of Multiple Sclerosis Worldwide: Insights from The Atlas of MS, Third Edition, published in 2020, a total of 2.8 million people are estimated to live with MS worldwide (35.9 per 100,000 population).
Various studies are investigating the use of TPE in several chronic diseases. In September 2023, a team of researchers in Japan published a study ‘Serum Immunoglobulin G Level Reduction is a Predictor of Short-Term Improvement in Patients with Myasthenia Gravis Undergoing Plasmapheresis,’ in the journal Therapeutic Apheresis and Dialysis. The study investigated the serological factors in predicting symptom improvement in Myasthenia Gravis (MG) patients who underwent plasmapheresis and found that reduction in immunoglobulin G helps improve the symptoms of MG patients who underwent plasmapheresis.
Emergence of COVID-19 is fueling the therapeutic plasma exchange market expansion. Plasma exchange therapy effectively removes pro-inflammatory factors that are evident in patients with SARS-CoV-2 infection. Several studies have reported that plasmapheresis aids in improving survival in patients with severe COVID-19. One study ‘Therapeutic Plasma Exchange in Adults with Severe COVID-19 Infection’, published in October 2020, achieved zero mortality in patients with severe COVID-19 who received 5 sessions of plasmapheresis.
According to the latest therapeutic plasma exchange market analysis, North America held largest share in 2022. High prevalence of neurological disorders is fueling the market dynamics of the region. According to the study ‘Burden of Neurological Disorders Across the US from 1990-2017 A Global Burden of Disease Study’, published in November 2020, stroke (3.58 million DALYs), Alzheimer’s disease and other dementias (2.55 million DALYs), and migraine (2.40 million DALYs) were the most burdensome neurological disorders in the U.S. in terms of absolute number of DALYs.
Therapeutic plasma exchange manufacturers are offering advanced and efficient TPE machines with state-of-the-art technology to differentiate themselves from other companies. They are investing in research and development to improve TPE technology and increase their therapeutic plasma exchange market share.
Asahi Kasei Corporation, Baxter International, Inc., Terumo Corporation, B. Braun SE, Fresenius Kabi AG, SB-Kawasumi Laboratories, Inc., Haemonetics Corporation, Cerus Corporation, Charles River Laboratories, and Medica S.p.A. are major therapeutic plasma exchange companies.
Each of these players has been profiled in the therapeutic plasma exchange market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 1.5 Bn |
| Market Forecast Value in 2031 | US$ 2.9 Bn |
| Growth Rate (CAGR) | 7.5% |
| Forecast Period | 2023 to 2031 |
| Historical Data Available for | 2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Regions Covered |
|
| Countries Covered |
|
| Market Segmentation |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 1.5 Bn in 2022
It is projected to grow at a CAGR of 7.5% from 2023 to 2031
Rise in prevalence of chronic diseases and R&D in therapeutic plasma exchange
The hospitals end-user segment held the largest share in 2022
North America held largest share in 2022
Asahi Kasei Corporation, Baxter International, Inc., Terumo Corporation, B. Braun SE, Fresenius Kabi AG, SB-Kawasumi Laboratories, Inc., Haemonetics Corporation, Cerus Corporation, Charles River Laboratories, and Medica S.p.A.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Therapeutic Plasma Exchange Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Therapeutic Plasma Exchange Market Analysis and Forecast, 2023–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Therapeutic Plasma Exchange Market Analysis and Forecast, by Disease Indication
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Indication, 2023–2031
6.3.1. Neurological Disorders
6.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
6.3.1.2. Myasthenia Gravis
6.3.1.3. Multiple Sclerosis
6.3.1.4. Neuromyelitis Optica
6.3.1.5. Guillain-Barre Syndrome
6.3.2. Renal Disorders
6.3.2.1. Post-renal Transplant Rejection
6.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
6.3.2.3. Wegener’s Granulomatosis
6.3.3. Hematology Disorders
6.3.3.1. Thrombotic Thrombocytopenic Purpura
6.3.3.2. Hemolytic Uremic Syndrome
6.3.3.3. Cryoglobulinemia
6.3.3.4. Multiple Myeloma
6.3.3.5. Metabolic Disorders
6.3.3.6. Homozygous Familial Hypercholesterolemia
6.3.3.7. Fulminant Wilson’s Disease
6.3.4. Others
6.4. Market Attractiveness Analysis, by Disease Indication
7. Global Therapeutic Plasma Exchange Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2023–2031
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.3.3. Ambulatory Surgical Centers
7.4. Market Attractiveness Analysis, by End-user
8. Global Therapeutic Plasma Exchange Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2023–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Therapeutic Plasma Exchange Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Disease Indication, 2023–2031
9.3.1. Neurological Disorders
9.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
9.3.1.2. Myasthenia Gravis
9.3.1.3. Multiple Sclerosis
9.3.1.4. Neuromyelitis Optica
9.3.1.5. Guillain-Barre Syndrome
9.3.2. Renal Disorders
9.3.2.1. Post-renal Transplant Rejection
9.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
9.3.2.3. Wegener’s Granulomatosis
9.3.3. Hematology Disorders
9.3.3.1. Thrombotic Thrombocytopenic Purpura
9.3.3.2. Hemolytic Uremic Syndrome
9.3.3.3. Cryoglobulinemia
9.3.3.4. Multiple Myeloma
9.3.3.5. Metabolic Disorders
9.3.3.6. Homozygous Familial Hypercholesterolemia
9.3.3.7. Fulminant Wilson’s Disease
9.3.4. Others
9.4. Market Value Forecast, by End-user, 2023–2031
9.4.1. Hospitals
9.4.2. Specialty Clinics
9.4.3. Ambulatory Surgical Centers
9.5. Market Value Forecast, by Country, 2023–2031
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Disease Indication
9.6.2. By End-user
9.6.3. By Country
10. Europe Therapeutic Plasma Exchange Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Disease Indication, 2023–2031
10.3.1. Neurological Disorders
10.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
10.3.1.2. Myasthenia Gravis
10.3.1.3. Multiple Sclerosis
10.3.1.4. Neuromyelitis Optica
10.3.1.5. Guillain-Barre Syndrome
10.3.2. Renal Disorders
10.3.2.1. Post-renal Transplant Rejection
10.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
10.3.2.3. Wegener’s Granulomatosis
10.3.3. Hematology Disorders
10.3.3.1. Thrombotic Thrombocytopenic Purpura
10.3.3.2. Hemolytic Uremic Syndrome
10.3.3.3. Cryoglobulinemia
10.3.3.4. Multiple Myeloma
10.3.3.5. Metabolic Disorders
10.3.3.6. Homozygous Familial Hypercholesterolemia
10.3.3.7. Fulminant Wilson’s Disease
10.3.4. Others
10.4. Market Value Forecast, by End-user, 2023–2031
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.4.3. Ambulatory Surgical Centers
10.4.4. Others
10.5. Market Value Forecast, by Country/Sub-region, 2023–2031
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Disease Indication
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific Therapeutic Plasma Exchange Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Disease Indication, 2023–2031
11.3.1. Neurological Disorders
11.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
11.3.1.2. Myasthenia Gravis
11.3.1.3. Multiple Sclerosis
11.3.1.4. Neuromyelitis Optica
11.3.1.5. Guillain-Barre Syndrome
11.3.2. Renal Disorders
11.3.2.1. Post-renal Transplant Rejection
11.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
11.3.2.3. Wegener’s Granulomatosis
11.3.3. Hematology Disorders
11.3.3.1. Thrombotic Thrombocytopenic Purpura
11.3.3.2. Hemolytic Uremic Syndrome
11.3.3.3. Cryoglobulinemia
11.3.3.4. Multiple Myeloma
11.3.3.5. Metabolic Disorders
11.3.3.6. Homozygous Familial Hypercholesterolemia
11.3.3.7. Fulminant Wilson’s Disease
11.3.4. Others
11.4. Market Value Forecast, by End-user, 2023–2031
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.4.3. Ambulatory Surgical Centers
11.4.4. Others
11.5. Market Value Forecast, by Country/Sub-region, 2023–2031
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Disease Indication
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America Therapeutic Plasma Exchange Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Disease Indication, 2023–2031
12.3.1. Neurological Disorders
12.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
12.3.1.2. Myasthenia Gravis
12.3.1.3. Multiple Sclerosis
12.3.1.4. Neuromyelitis Optica
12.3.1.5. Guillain-Barre Syndrome
12.3.2. Renal Disorders
12.3.2.1. Post-renal Transplant Rejection
12.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
12.3.2.3. Wegener’s Granulomatosis
12.3.3. Hematology Disorders
12.3.3.1. Thrombotic Thrombocytopenic Purpura
12.3.3.2. Hemolytic Uremic Syndrome
12.3.3.3. Cryoglobulinemia
12.3.3.4. Multiple Myeloma
12.3.3.5. Metabolic Disorders
12.3.3.6. Homozygous Familial Hypercholesterolemia
12.3.3.7. Fulminant Wilson’s Disease
12.3.4. Others
12.4. Market Value Forecast, by End-user, 2023–2031
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.4.3. Ambulatory Surgical Centers
12.4.4. Others
12.5. Market Value Forecast, by Country/Sub-region, 2023–2031
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Disease Indication
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa Therapeutic Plasma Exchange Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Disease Indication, 2023–2031
13.3.1. Neurological Disorders
13.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
13.3.1.2. Myasthenia Gravis
13.3.1.3. Multiple Sclerosis
13.3.1.4. Neuromyelitis Optica
13.3.1.5. Guillain-Barre Syndrome
13.3.2. Renal Disorders
13.3.2.1. Post-renal Transplant Rejection
13.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
13.3.2.3. Wegener’s Granulomatosis
13.3.3. Hematology Disorders
13.3.3.1. Thrombotic Thrombocytopenic Purpura
13.3.3.2. Hemolytic Uremic Syndrome
13.3.3.3. Cryoglobulinemia
13.3.3.4. Multiple Myeloma
13.3.3.5. Metabolic Disorders
13.3.3.6. Homozygous Familial Hypercholesterolemia
13.3.3.7. Fulminant Wilson’s Disease
13.3.4. Others
13.4. Market Value Forecast, by End-user, 2023–2031
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.4.3. Ambulatory Surgical Centers
13.4.4. Others
13.5. Market Value Forecast, by Country/Sub-region, 2023–2031
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Disease Indication
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Asahi Kasei Corporation
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Baxter International, Inc.
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Terumo Corporation
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. B. Braun SE
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Fresenius Kabi AG
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. SB-Kawasumi Laboratories, Inc.
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Haemonetics Corporation
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Cerus Corporation
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. Charles River Laboratories
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Medica S.p.A.
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
List of Tables
Table 01: Global Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2031
Table 02: Global Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by End-user, 2023–2031
Table 03: Global Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Region, 2023–2031
Table 04: North America Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Country, 2023–2031
Table 05: North America Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2031
Table 06: North America Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by End-user, 2023–2031
Table 07: Europe Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 08: Europe Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2031
Table 09: Europe Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by End-user, 2023–2031
Table 10: Asia Pacific Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 11: Asia Pacific Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2031
Table 12: Asia Pacific Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by End-user, 2023–2031
Table 13: Latin America Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 14: Latin America Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2031
Table 15: Latin America Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by End-user, 2023–2031
Table 16: Middle East & Africa Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 17: Middle East & Africa Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2031
Table 18: Middle East & Africa Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by End-user, 2023–2031
List of Figures
Figure 01: Global Therapeutic Plasma Exchange Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2031
Figure 02: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn), by Disease Indication, 2022
Figure 03: Global Therapeutic Plasma Exchange Market Value Share, by Disease Indication, 2022
Figure 04: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn), by End-user, 2022
Figure 05: Global Therapeutic Plasma Exchange Market Value Share, by End-user, 2022
Figure 06: Global Therapeutic Plasma Exchange Market Value Share, by Region, 2022
Figure 07: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, 2023–2031
Figure 08: Global Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication, 2023 and 2031
Figure 09: Global Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication, 2022-2031
Figure 10: Global Therapeutic Plasma Exchange Market Value Share Analysis, by End-user, 2023 and 2031
Figure 11: Global Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user, 2022-2031
Figure 12: Global Therapeutic Plasma Exchange Market Value Share Analysis, by Region, 2023 and 2031
Figure 13: Global Therapeutic Plasma Exchange Market Attractiveness Analysis, by Region, 2022-2031
Figure 14: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 15: North America Therapeutic Plasma Exchange Market Attractiveness Analysis, by Country, 2023–2031
Figure 16: North America Therapeutic Plasma Exchange Market Value Share Analysis, by Country, 2023 and 2031
Figure 17: North America Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication, 2023 and 2031
Figure 18: North America Therapeutic Plasma Exchange Market Value Share Analysis, by End-user, 2023 and 2031
Figure 19: North America Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication, 2022–2031
Figure 20: North America Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user, 2022–2031
Figure 21: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 22: Europe Therapeutic Plasma Exchange Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 23: Europe Therapeutic Plasma Exchange Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 24: Europe Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication, 2023 and 2031
Figure 25: Europe Therapeutic Plasma Exchange Market Value Share Analysis, by End-user, 2023 and 2031
Figure 26: Europe Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication, 2022–2031
Figure 27: Europe Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user, 2022–2031
Figure 28: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 29: Asia Pacific Therapeutic Plasma Exchange Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 30: Asia Pacific Therapeutic Plasma Exchange Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 31: Asia Pacific Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication, 2023 and 2031
Figure 32: Asia Pacific Therapeutic Plasma Exchange Market Value Share Analysis, by End-user, 2023 and 2031
Figure 33: Asia Pacific Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication, 2022–2031
Figure 34: Asia Pacific Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user, 2022–2031
Figure 35: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 36: Latin America Therapeutic Plasma Exchange Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 37: Latin America Therapeutic Plasma Exchange Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 38: Latin America Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication, 2023 and 2031
Figure 39: Latin America Therapeutic Plasma Exchange Market Value Share Analysis, by End-user, 2023 and 2031
Figure 40: Latin America Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication, 2022–2031
Figure 41: Latin America Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user, 2022–2031
Figure 42: Middle East & Africa Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 43: Middle East & Africa Therapeutic Plasma Exchange Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 44: Middle East & Africa Therapeutic Plasma Exchange Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 45: Middle East & Africa Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication, 2023 and 2031
Figure 46: Middle East & Africa Therapeutic Plasma Exchange Market Value Share Analysis, by End-user, 2023 and 2031
Figure 47: Middle East & Africa Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication, 2022–2031
Figure 48: Middle East & Africa Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Therapeutic Plasma Exchange Market
